David Alejandro Cabrera-Gaytán

Estimated Direct Costs of Patients Hospitalized for Severe Acute RespiratoryIllness in the Mexican Social Security Institute. Winter Season, 2013-2014

Objective: To estimate the direct cost in patients hospitalized for severe acute respiratory infection, 2013-2014 winter season. Material and methods: We analyzed data on all hospitalizations with severe acute respiratory infection (SARI) and laboratory-confirmed influenza and the days of hospital stay per patient were determined, according to the level of medical care; so the cost bed/day unit cost of 1) was added a query emergency, 2) a survey of basic clinical laboratory, 3) a chest radiograph, 4) antiviral treatment and 5) confirmatory laboratory diagnosis; by a rising cost of illness approach. Costs were converted to U.S. dollars. Results: 13,242 cases were reported, of which 3,214 were excluded and removed, the universe of study was 10,028 inpatients. The costs in secondary care were

Association of Pulmonary Tuberculosis and HIV in the Mexican Institute of Social Security, 2006-2014.

874,848,088 (US

Síndrome metabólico en personal de salud de una unidad de medicina familiar

66,608,910), while in third level was

Panorama epidemiológico de la tos ferina 19 años de estudio epidemiológico en el Instituto Mexicano del Seguro Social

37,435,173 (US

Pertussis in Mexico, an epidemiological overview. A study of 19 years at the Instituto Mexicano del Seguro Social

2,850,227), making the total cost was

Perfil sexual de las mujeres con citología cervical de una unidad de primer nivel

912,283,262 (US

Association of Notified Cases and Treatment Success Rates in Pulmonary Tuberculosis

69,459,137). By delegation, there was heterogeneity in costs and days stay. Conclusions: It essential to establish appropriate preventive interventions and perform a comprehensive patient care.

Epidemiological surveillance of meningeal and encephalic syndrome in the Mexican Social Security Institute, 2012–2014

Background Tuberculosis and HIV remain a public health problem in developed countries. The objective of this study was to analyze the incidence trends of pulmonary TB and HIV comorbidity and treatment outcomes according to HIV during the period 2006 to 2014 in the Mexican Institute of Social Security. Methods Analyzed data from this registry including pulmonary tuberculosis patients aged 15 years and older who had been diagnosed during the years 2006 to 2014 in the Mexican Institute of Social Security. The outcomes that we use were incidents rate, failure to treatment and death. Regression models were used to quantify associations between pulmonary tuberculosis and HIV mortality. Results During the study period, 31,352 patients were registered with pulmonary tuberculosis. The incidence rate observed during 2014 was 11.6 case of PTB per 100,000. The incidence rate for PTB and HIV was 0.345 per 100,000. The PTB incidence rate decreased by 0.07%, differences found in the PTB incidence rate by sex since in women decreased by 5.52% and in man increase by 3.62%. The pulmonary TB with HIV incidence rate decreased by 16.3% during the study period (In women increase 4.81% and in man decrease 21.6%). Analysis of PTB associated with HIV by age groups revealed that the highest incidence rates were observed for the 30 to 44 years old group. Meanwhile, the highest incidence rates of PTB without HIV occurred among the 60 and more years old individuals. We did not find statistically significant differences between treatment failure and PTB patients with HIV and without HIV. The treatment failure was associated with sex and the region of the patient. We found a strong association between HIV and the probability of dying during treatment. Our data suggested that patients suffering from both conditions (PTB and HIV) have no difference in the probability of failure of treatment contrary to other reports. Hypotheses to this is adherence to tuberculosis treatment with people living with HIV/AIDS, detection of PTB in patients suffering from HIV/AIDS or PTB patients on antiretroviral therapy were more likely to have successful treatment outcomes than those not on antiretroviral treatment. We have found that PTB and HIV increases the probability of dying during treatment compared to the cases of PTB without HIV, consistent with published other study HIV increases the mortality rates associated with PTB. Conclusions No association between pulmonary tuberculosis with HIV and treatment failure was observed, but pulmonary tuberculosis and HIV increases the probability of dying during treatment compared to the pulmonary tuberculosis cases without HIV.